Ovid Therapeutics Inc   (OVID)
Other Ticker:  
Price: $3.4000 $0.00 0.000%
Day's High: $3.45 Week Perf: -7.61 %
Day's Low: $ 3.31 30 Day Perf: -12.14 %
Volume (M): 116 52 Wk High: $ 4.14
Volume (M$): $ 394 52 Wk Avg: $3.39
Open: $3.45 52 Wk Low: $1.90

 Market Capitalization (Millions $) 240
 Shares Outstanding (Millions) 71
 Employees 51
 Revenues (TTM) (Millions $) 0
 Net Income (TTM) (Millions $) -49
 Cash Flow (TTM) (Millions $) -1
 Capital Exp. (TTM) (Millions $) 0

Ovid Therapeutics Inc
Ovid Therapeutics Inc. is a biopharmaceutical company that was founded in 2014 by a team of experienced industry leaders and scientists with the goal of developing treatments for rare neurological diseases. The company is headquartered in New York, NY, and is publicly traded on the NASDAQ under the symbol OVID.

The focus of Ovid Therapeutics is on developing innovative therapeutics for patients with rare neurological disorders, including developmental and epileptic encephalopathies (DEEs) and Angelman syndrome. These disorders are caused by genetic mutations that disrupt proper brain function and often lead to severe intellectual disability and other developmental delays.

Ovid Therapeutics' lead drug candidate, OV101, is a highly selective small molecule that is being developed to treat both Angelman syndrome and Fragile X syndrome. These conditions are caused by a deficiency in the inhibitory neurotransmitter GABA, which OV101 is designed to enhance. OV101 is currently in clinical trials, with Phase 3 studies ongoing in Angelman syndrome and Phase 2 trials in Fragile X syndrome.

In addition to OV101, Ovid Therapeutics is developing several other drug candidates, including OV935, a highly selective dual inhibitor of enzymes that regulate the production of neurotransmitters glutamate and GABA. OV935 is being developed as a potential treatment for both DEEs and epileptic spasms.

Ovid Therapeutics has formed partnerships with several leading academic and research institutions to advance its drug development programs. The company has also received funding from several venture capital firms.

Overall, Ovid Therapeutics is a leading biopharmaceutical company focused on developing innovative therapeutics for patients with rare neurological disorders. With a strong pipeline of drug candidates and a highly experienced management team, Ovid is well-positioned to make a meaningful impact in the lives of patients and families affected by these devastating conditions.

   Company Address: 441 Ninth Avenue New York 10001 NY
   Company Phone Number: 661-7661   Stock Exchange / Ticker: NASDAQ OVID
   OVID is expected to report next financial results on March 12, 2024.


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Ovid Therapeutics Inc

Ovid Therapeutics' Exceptional Revenue Surge Propels Major Pharmaceutical Preparations Company's Fiscal Success in Q3 2023

Ovid Therapeutics Inc, a biopharmaceutical company focused on developing treatments for rare epilepsies and seizure-related disorders, recently reported its financial results for the third quarter of 2023. Despite a decrease in its loss per share compared to the previous year and an improvement in earnings per share, the company reported a net deficit of $11.252 million for the third quarter.
One positive aspect of the financial report was the significant increase in revenue. Ovid Therapeutics Inc's revenue surged by an impressive 881.553% to $0.11 million from $0.01 million in the same period last year. Additionally, revenue showed a sequential increase of 45.296% from $0.08 million. This growth in revenue is in line with the performance of the company's peers in the Major Pharmaceutical Preparations sector, which experienced an average top-line rise of 1.66% in the same period.

Earnings announcement

Ovid Therapeutics and Ligand Pharmaceuticals Forge a $30 Million Agreement, Boosting Ovid's Financial Stability and Paving the Way for Potential Breakthrough Treatment

Published Wed, Oct 18 2023 12:00 PM UTC

In an exciting development for the biopharmaceutical industry, Ovid Therapeutics Inc. and Ligand Pharmaceuticals Incorporated have announced a groundbreaking $30 million agreement that will extend Ovid's financial runway and potentially revolutionize treatment for individuals with rare epilepsies and seizure-related disorders. This strategic collaboration involves ...

Ovid Therapeutics Inc

Ovid Therapeutics Inc Reports $0.075 Million Revenue in Q2 2023, Shows Signs of Positive Financial Turnaround

Ovid Therapeutics Inc is a pharmaceutical company that focuses on developing novel treatments for rare neurological disorders. The company's recent financial disclosures reveal both positive and negative trends in their financial performance.
In the April to June 30 2023 financial period, Ovid Therapeutics Inc disclosed $0.075 million in revenue. Although this may seem like a small amount, it is still a sign of growth for the company. Additionally, the company reported a net shortfall of $-12.408 million during this period, which is an improvement compared to the $-14.588 million deficit reported in the same period the previous year. This indicates that the company is making progress in managing their expenses and reducing their losses.

Ovid Therapeutics Inc

Ovid Therapeutics Inc Reports Decreased Net Loss, But Revenue Plummets by -95%

Investors in Ovid Therapeutics Inc should exercise caution ahead of the company's next financial earnings report, scheduled for May 09, 2023. While the latest fiscal period saw some improvements in the company's finances, there are still warning signs that suggest OVID may continue to face challenges.
During the latest fiscal period, OVID saw its net loss decrease to $-0.19 per share, compared to $-0.23 the previous year. However, the company's revenue plummeted by -95.423% to just $0.07 million, a significant decline from the $1.45 million reported in the same period a year ago. The company did experience a slight revenue boost sequentially, rising by 42.956% from $0.05 million.


Ovid Therapeutics Inc's Segments
• View Complete Report


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com